<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04434001</url>
  </required_header>
  <id_info>
    <org_study_id>ZEPLAST-PED</org_study_id>
    <nct_id>NCT04434001</nct_id>
  </id_info>
  <brief_title>ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery</brief_title>
  <acronym>ZEPLAST-PED</acronym>
  <official_title>ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery Randomized Controlled Pilot Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Donato</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Donato</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In pediatric patients (newborns and infants weighing less than 10 kg) undergoing cardiac
      surgery with extracorporeal circulation postoperative bleeding represents a known
      complication with a significant impact on outcome. Fresh frozen plasma (FFP) for bleeding
      management is associated, particularly in this kind of patients, to volume overload and a
      significative increase of Transfusion Related Acute Lung Injury (TRALI), further worsening
      the postoperative outcome. In the adult patient FFP employment could be almost completely
      canceled by administration of concentrated hemostatic components - the fibrinogen concentrate
      and prothrombin complex concentrate (PCC). We designed this phase II pilot study to establish
      whether an analogous strategy, modified accordingly to pediatric physiology, could be safely
      and successfully applied in newborns and infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population will be randomized to two groups: ZEPLAST and control, respectively.

      The two groups will receive the same priming solution (containing Red Blood Cells and albumin
      5%) and heparin/protamine management. In both groups coagulation will be assessed with
      rotational thromboelastometry (ROTEM - EXTEM, INTEM, HEPTEM and FIBTEM tests) after heparin
      antagonization. In case of bleeding, coagulopathies will be treated differently:

        -  in the ZEPLAST group, fibrinogen deficiency (FIBTEM Maximum Clot Firmness MCF &lt; 8 mm)
           will be treated with 30 mg/kg of concentrated fibrinogen; low thrombin generation (EXTEM
           Clotting Time CT &gt; 100 s) will be treated with 20 mg/kg of prothrombin complex
           concentrate;

        -  in the control group, coagulopathies will be treated with 10-20 ml/kg of FFP. In case of
           refractory bleeding, PCC and fibrinogen can be administered as a rescue treatment.

      Further ROTEM tests will be performed at 24 and 48 hours post surgery. Outcome parameters
      will be collected at the same timepoints.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">October 9, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transfusion of Fresh Frozen Plasma (FFP)</measure>
    <time_frame>First 48 hours after surgery</time_frame>
    <description>Number of patients transfused with FFP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative bleeding</measure>
    <time_frame>First 12, 24 and 48 hours after surgery</time_frame>
    <description>Amount of blood collected by chest drainages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe bleeding</measure>
    <time_frame>First 12 hours after surgery</time_frame>
    <description>Number of patients who experienced severe bleeding (higher than 30 ml/kg in the first 12 hours after surgery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical re-exploration for bleeding</measure>
    <time_frame>First 12, 24 and 48 hours after surgery</time_frame>
    <description>Number of patients requiring surgical re-exploration due to bleeding (bleeding with no coagulopathies detected or refractory to pharmacological treatment)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bleeding</condition>
  <condition>Cardiac Defect</condition>
  <condition>Surgery--Complications</condition>
  <condition>Fibrinogenopenia; Acquired</condition>
  <condition>Transfusion-Related Acute Lung Injury</condition>
  <condition>Transfusion-Associated Circulatory Overload</condition>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>ZEPLAST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In case of bleeding and:
CT INTEM &gt; CT HEPTEM by 25% : give protamine 0.25 mg/kg;
MCF FIBTEM &lt; 8 mm : give Fibrinogen Concentrate 30 mg/kg;
CT EXTEM &gt; 100 s : give Prothrombin Complex Concentrate 20 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In case of bleeding and:
CT INTEM &gt; CT HEPTEM by 25% : give protamine 0.25 mg/kg;
fibrinogen and/or thrombin generation deficiency : give FFP 10-20 ml/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibrinogen Concentrate Human</intervention_name>
    <description>Treatment of acquired postoperatively fibrinogen deficiency as assessed by ROTEM FIBTEM test.</description>
    <arm_group_label>ZEPLAST</arm_group_label>
    <other_name>Haemocomplettan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prothrombin Complex Concentrate</intervention_name>
    <description>Treatment of acquired postoperatively thrombin generation deficiency as assessed by ROTEM EXTEM test.</description>
    <arm_group_label>ZEPLAST</arm_group_label>
    <other_name>Confidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fresh Frozen Plasma</intervention_name>
    <description>Treatment of acquired postoperative coagulopathy as assessed by ROTEM FIBTEM and INTEM tests.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newborns and infants with weight lower than 10 kg undergoing cardiac surgery with
             extracorporeal circulation:

          -  informed consent signed by both parents or legal guardian.

        Exclusion Criteria:

          -  emergency surgery;

          -  known congenital coagulopathy or suspected based on anamnesis;

          -  participation to other clinical trials;

          -  known hypersensitivity to components and excipients of FFP , prothrombin complex
             concentrate or fibrinogen concentrate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Ranucci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico San Donato</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco Ranucci, MD</last_name>
    <phone>+390252774754</phone>
    <email>marco.ranucci@grupposandonato.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ekaterina Baryshnikova, PhD</last_name>
    <phone>+390252774754</phone>
    <email>ekaterina.baryshnikova@grupposandonato.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>MI</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Ranucci, MD</last_name>
      <phone>+390252774754</phone>
      <email>marco.ranucci@grupposandonato.it</email>
    </contact>
    <contact_backup>
      <last_name>Ekaterina Baryshnikova, PhD</last_name>
      <phone>+390252774754</phone>
      <email>ekaterina.baryshnikova@grupposandonato.it</email>
    </contact_backup>
    <investigator>
      <last_name>Marco Ranucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ekaterina Baryshnikova, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Moore SB. Transfusion-related acute lung injury (TRALI): clinical presentation, treatment, and prognosis. Crit Care Med. 2006 May;34(5 Suppl):S114-7. Review.</citation>
    <PMID>16617254</PMID>
  </reference>
  <reference>
    <citation>Ranucci M, Baryshnikova E. Fibrinogen supplementation after cardiac surgery: insights from the Zero-Plasma trial (ZEPLAST). Br J Anaesth. 2016 May;116(5):618-23. doi: 10.1093/bja/aev539. Epub 2016 Feb 17.</citation>
    <PMID>26893405</PMID>
  </reference>
  <reference>
    <citation>Bianchi P, Cotza M, Beccaris C, Silvetti S, Isgrò G, Pomè G, Giamberti A, Ranucci M; Surgical and Clinical Outcome REsearch (SCORE) group. Early or late fresh frozen plasma administration in newborns and small infants undergoing cardiac surgery: the APPEAR randomized trial. Br J Anaesth. 2017 May 1;118(5):788-796. doi: 10.1093/bja/aex069.</citation>
    <PMID>28510741</PMID>
  </reference>
  <reference>
    <citation>Ranucci M, Bianchi P, Cotza M, Beccaris C, Silvetti S, Isgrò G, Giamberti A, Baryshnikova E. Fibrinogen levels and postoperative chest drain blood loss in low-weight (&lt;10 kg) children undergoing cardiac surgery. Perfusion. 2019 Nov;34(8):629-636. doi: 10.1177/0267659119854246. Epub 2019 Jun 28.</citation>
    <PMID>31250738</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 12, 2020</study_first_submitted>
  <study_first_submitted_qc>June 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Donato</investigator_affiliation>
    <investigator_full_name>Marco Ranucci</investigator_full_name>
    <investigator_title>Head of Cardiothoracic and Vascular Anesthesia and Intensive Care</investigator_title>
  </responsible_party>
  <keyword>bleeding</keyword>
  <keyword>pediatric cardiac surgery</keyword>
  <keyword>fresh frozen plasma</keyword>
  <keyword>fibrinogen concentrate</keyword>
  <keyword>prothrombin complex concentrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Transfusion-Related Acute Lung Injury</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Transfusion Reaction</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

